Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients

Pei-Wen Chiang, David G. Beer, Wan Li Wei, Mark B. Orringer, David M. Kurnit

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

We used TaqMan PCR to detect quantitative anomalies of tumor markers in both tumor and serum DNA from esophageal cancer patients. We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. These amplifications were corroborated by Southern blots. We then showed the potential of this methodology to detect quantitative anomalies of erbB-2 in serum DNA from individuals with a corresponding amplification in the tumor. The capability of TaqMan PCR to detect abnormalities in serum of esophageal cancer patients creates an opportunity to diagnose esophageal cancer and to monitor the outcome of treatment with a blood test.

Original languageEnglish (US)
Pages (from-to)1381-1386
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number6
StatePublished - Jun 1999
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Carcinoma
Serum
Neoplasms
Polymerase Chain Reaction
DNA
Hematologic Tests
Tumor Biomarkers
Southern Blotting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chiang, P-W., Beer, D. G., Wei, W. L., Orringer, M. B., & Kurnit, D. M. (1999). Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clinical Cancer Research, 5(6), 1381-1386.

Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. / Chiang, Pei-Wen; Beer, David G.; Wei, Wan Li; Orringer, Mark B.; Kurnit, David M.

In: Clinical Cancer Research, Vol. 5, No. 6, 06.1999, p. 1381-1386.

Research output: Contribution to journalArticle

Chiang, P-W, Beer, DG, Wei, WL, Orringer, MB & Kurnit, DM 1999, 'Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients', Clinical Cancer Research, vol. 5, no. 6, pp. 1381-1386.
Chiang P-W, Beer DG, Wei WL, Orringer MB, Kurnit DM. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clinical Cancer Research. 1999 Jun;5(6):1381-1386.
Chiang, Pei-Wen ; Beer, David G. ; Wei, Wan Li ; Orringer, Mark B. ; Kurnit, David M. / Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 6. pp. 1381-1386.
@article{0012210f43584bcb9c92d95875b5431c,
title = "Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients",
abstract = "We used TaqMan PCR to detect quantitative anomalies of tumor markers in both tumor and serum DNA from esophageal cancer patients. We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. These amplifications were corroborated by Southern blots. We then showed the potential of this methodology to detect quantitative anomalies of erbB-2 in serum DNA from individuals with a corresponding amplification in the tumor. The capability of TaqMan PCR to detect abnormalities in serum of esophageal cancer patients creates an opportunity to diagnose esophageal cancer and to monitor the outcome of treatment with a blood test.",
author = "Pei-Wen Chiang and Beer, {David G.} and Wei, {Wan Li} and Orringer, {Mark B.} and Kurnit, {David M.}",
year = "1999",
month = "6",
language = "English (US)",
volume = "5",
pages = "1381--1386",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients

AU - Chiang, Pei-Wen

AU - Beer, David G.

AU - Wei, Wan Li

AU - Orringer, Mark B.

AU - Kurnit, David M.

PY - 1999/6

Y1 - 1999/6

N2 - We used TaqMan PCR to detect quantitative anomalies of tumor markers in both tumor and serum DNA from esophageal cancer patients. We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. These amplifications were corroborated by Southern blots. We then showed the potential of this methodology to detect quantitative anomalies of erbB-2 in serum DNA from individuals with a corresponding amplification in the tumor. The capability of TaqMan PCR to detect abnormalities in serum of esophageal cancer patients creates an opportunity to diagnose esophageal cancer and to monitor the outcome of treatment with a blood test.

AB - We used TaqMan PCR to detect quantitative anomalies of tumor markers in both tumor and serum DNA from esophageal cancer patients. We demonstrated the potential of this methodology by detecting erbB-2 amplifications in a plurality of esophageal tumor samples. These amplifications were corroborated by Southern blots. We then showed the potential of this methodology to detect quantitative anomalies of erbB-2 in serum DNA from individuals with a corresponding amplification in the tumor. The capability of TaqMan PCR to detect abnormalities in serum of esophageal cancer patients creates an opportunity to diagnose esophageal cancer and to monitor the outcome of treatment with a blood test.

UR - http://www.scopus.com/inward/record.url?scp=0032979756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032979756&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1381

EP - 1386

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -